ZFIN ID: ZDB-PUB-161011-7
Using zebrafish models of leukemia to streamline drug screening and discovery
Deveau, A.P., Bentley, V.L., Berman, J.N.
Date: 2017
Source: Experimental hematology   45: 1-9 (Review)
Registered Authors: Bentley, Victoria, Berman, Jason, Deveau, Adam
Keywords: none
MeSH Terms:
  • Animals
  • Animals, Genetically Modified
  • Antineoplastic Agents/pharmacology*
  • Antineoplastic Agents/therapeutic use
  • Disease Models, Animal
  • Drug Discovery*
  • Drug Evaluation, Preclinical*
  • Genomics/methods
  • High-Throughput Screening Assays*
  • Humans
  • Leukemia/drug therapy
  • Phenotype
  • Xenograft Model Antitumor Assays
  • Zebrafish*
PubMed: 27720937 Full text @ Exp. Hematol.
Current treatment strategies for acute leukemias largely rely on nonspecific cytotoxic drugs that result in high therapy-related morbidity and mortality. Cost effective, pertinent animal models are needed to link in vitro studies with the development of new therapeutic agents in clinical trials on a high-throughput scale. However, targeted therapies have had limited success moving from bench-to-clinic, often due to unexpected off-target effects. The zebrafish has emerged as a reliable in vivo tool for modeling human leukemia. Zebrafish genetic and xenograft models of acute leukemia provide an unprecedented opportunity to conduct rapid phenotype-based screens. This prospect allows for the identification of relevant therapies, while simultaneously evaluating drug toxicity, circumventing the limitations of target-centric approaches.